Skopos Labs, Inc. Apellis Pharmaceuticals, Inc. Transaction History
Skopos Labs, Inc.
- $330 Million
- Q4 2024
A detailed history of Skopos Labs, Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Skopos Labs, Inc. holds 241 shares of APLS stock, worth $6,935. This represents 0.0% of its overall portfolio holdings.
Number of Shares
241
Previous 27
792.59%
Holding current value
$6,935
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding APLS
# of Institutions
302Shares Held
112MCall Options Held
3.85MPut Options Held
1.09M-
Wellington Management Group LLP Boston, MA15.6MShares$448 Million0.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$342 Million14.88% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$320 Million4.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$282 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$167 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.16B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...